GW Pharma releases positive data on cannabidiol-based Phase III trial

pharmafile | September 28, 2016 | News story | Research and Development Epidiolex, GW Pharmaceuticals, Marijuana, Medical marijuana, cannabis 

GW Pharmaceuticals’ Epidiolex is designed to treat seizures in a rare form of epilepsy called Lennox-Gaustaut Syndrome. GW pharmaceuticals published results that showed patients taking a 20mg dose of Epidiolex saw their seizures drop on average 42% compared with 17% of those taking a placebo. Patients taking a 10mg dose were also found to experience a 37% drop against the 17% drop in the placebo group.

The news saw GW Pharmaceutical shares soar 26% to just over $124 a share, as of now. This is based on analysts predicting that, assuming approval, revenue for Epidiolex would be approximately $260 million for 2018, $570 million for 2019 before rising to $895 million by 2020.

The stumbling block on the way to approval is whether the FDA will take the step to bring a drug derived from cannabis to market. This would be the first such drug on the market and mean that it would also force the FDA to declare a medicinal use for cannabis, meaning it could no longer be listed as a schedule 1 drug. However, with this being the third positive Phase III trial, it seems that all the signs are positive for GW Pharmaceutical to gain approval for Epidiolex.

Ben Hargreaves

Related Content

GW Pharma’s cannabidiol gains EC approval

GW Pharmaceuticals has received European Commission (EC) approval for the type II variation application for …


NHS guidelines on prescription cannabis to be challenged in court

The cannabis guidelines followed by the NHS are set to be challenged in court by …


UK Home office reclassifies Epidyolex as a Schedule 5 drug

The Home Office has announced that the drug Epidyolex (cannabidiol) has been reclassified as a …

Latest content